{"doi":"10.1358/dot.2013.49.8.2002839","title":"Pharmacological strategies for preventing type 2 diabetes in\npatients with impaired glucose tolerance","abstract":null,"journal":"Drugs of Today","year":2013,"id":606139,"datarank":0.32958368660043297,"base_score":2.1972245773362196,"endowment":2.1972245773362196,"self_citation_contribution":0.32958368660043297,"citation_network_contribution":0.0,"self_endowment_contribution":0.32958368660043297,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":8,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1555879,"name":"Smith-Marsh, D.","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Pharmacological strategies for preventing type 2 diabetes in\npatients with impaired glucose tolerance","abstract":"Type 2 diabetes is an increasingly prevalent disease in the United States, and is associated with microvascular and macrovascular complications. Prediabetes, which is defined as impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT), increases the risk of development of type 2 diabetes. Lifestyle improvements, including weight loss and increased physical activity are effective in reducing the conversion of IGT to type 2 diabetes by 58%. However, lifestyle interventions alone may be difficult to maintain. Oral pharmacological agents used to treat type 2 diabetes that improve insulin sensitivity, preserve beta cell function and delay carbohydrate metabolism have been shown to prevent the progression of IGT to type 2 diabetes. The risk reduction of diabetes using metformin, pioglitazone, acarbose, valsartan and orlistat in clinical studies has ranged from 14 to 72%. Therefore, persons with IGT tolerance may benefit from pharmacological therapy to prevent the development of type 2 diabetes.","is_dataset_classified":null,"base_score":2.1972245773362196,"endowment":2.1972245773362196,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"23977667","pmcid":null,"openalex_id":"https://openalex.org/W2079830534","authors":[],"funders":[],"total_grants":0,"fwci":0.5503,"citation_percentile":0.66514428,"influential_citations":0,"citation_trend":[{"year":2015,"count":2},{"year":2016,"count":2},{"year":2018,"count":1},{"year":2019,"count":1},{"year":2022,"count":1},{"year":2025,"count":1}],"oa_status":"closed","license":null,"oa_locations":[{"url":"https://doi.org/10.1358/dot.2013.49.8.2002839","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/23977667","host_type":"repository"}],"fields_of_study":["Metabolism, Diabetes, and Cancer","Pharmacology and Obesity Treatment","Diabetes Treatment and Management"],"mesh_terms":["Diabetes Mellitus, Type 2","Humans","Hypoglycemic Agents","Life Style","Prediabetic State","Risk Factors","Weight Loss","Glucose Intolerance","Risk Reduction Behavior"],"keywords":["Medicine","Impaired glucose tolerance","Prediabetes","Type 2 diabetes","Acarbose","Metformin","Diabetes mellitus","Internal medicine","Impaired fasting glucose","Orlistat","Endocrinology","Insulin resistance","Weight loss","Obesity","Diabetes","Prevention","Glucose Intolerance"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-30T03:57:49.428087Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}